Search

Your search keyword '"Nodelman M"' showing total 2 results
Start Over Author "Nodelman M" Journal cancer gene therapy
2 results on '"Nodelman M"'

1. Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers

Author

Barry J. Sugarman, John A. Howe, Machemer T, Nodelman M, Daniel C. Maneval, Demers Gw, Shu Fen Wen, Nagabhushan Tl, Wills Ken N, Duane E. Johnson, Heidrun Engler, Shinoda J, Beltran J, and Iqbal Ahmed Cm

Subjects
Cancer Research, Blotting, Western, Genetic Vectors, Transplantation, Heterologous, Cytomegalovirus, Mice, Nude, Spleen, Mice, SCID, Interferon alpha-2, Gene delivery, Adenoviridae, Viral vector, Mice, In vivo, Interferon, Tumor Cells, Cultured, medicine, Animals, Humans, Neoplasm Metastasis, Molecular Biology, DNA Primers, Mice, Inbred BALB C, Mice, Inbred ICR, Reverse Transcriptase Polymerase Chain Reaction, business.industry, Interferon-alpha, Genetic Therapy, Neoplasms, Experimental, medicine.disease, Virology, Recombinant Proteins, Survival Rate, Transplantation, medicine.anatomical_structure, Cancer research, Molecular Medicine, Female, business, Cell Division, Chronic myelogenous leukemia, K562 cells, medicine.drug
Abstract

A recombinant adenovirus expressing human interferon alpha2b driven by the cytomegalovirus promoter, IACB, was shown to produce and secrete biologically active protein in vitro and in vivo. Intravenous administration of IACB in Buffalo rats resulted in circulating levels of biologically active human interferon at 70,000 international units/mL for up to 15 days. Distribution of interferon protein after IACB administration was different from that seen with the subcutaneous delivery of interferon protein. Higher levels of interferon protein were observed in liver and spleen after IACB delivery compared to protein delivery. The antitumor efficacy of IACB, as measured by suppression of tumor growth, was tested in athymic nude mice bearing established human tumor xenografts from different types of human cancer. Subcutaneous tumors most responsive to the intratumoral administration of IACB ranked as U87MG (glioblastoma) and K562 (chronic myelogenous leukemia), followed by Hep 3B (hepatocellular carcinoma) and LN229 cells (glioblastoma). Intravenous administration of IACB in animals bearing U87MG or Hep 3B xenografts was also effective in suppressing tumor growth, although to a lesser extent than the intratumoral administration. IACB was also tested in a metastatic model in beige/SCID mice generated with H69 (small cell lung carcinoma) cells and was found to prolong survival in tumor-bearing animals. This suggested that interferon gene delivery can be effective in suppressing tumor growth in a wide variety of cells.

Published
2001

2. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers.

Author

Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, Wen SF, Shinoda J, Beltran J, Nodelman M, Machemer T, Maneval DC, Nagabhushan TL, and Sugarman BJ

Subjects
Animals, Blotting, Western, Cell Division, Cytomegalovirus genetics, DNA Primers chemistry, Female, Humans, Interferon alpha-2, Interferon-alpha metabolism, Mice, Mice, Inbred BALB C, Mice, Inbred ICR, Mice, Nude, Mice, SCID, Neoplasm Metastasis, Neoplasms, Experimental mortality, Recombinant Proteins, Reverse Transcriptase Polymerase Chain Reaction, Survival Rate, Transplantation, Heterologous, Tumor Cells, Cultured, Adenoviridae genetics, Genetic Therapy methods, Genetic Vectors, Interferon-alpha genetics, Neoplasms, Experimental therapy
Abstract

A recombinant adenovirus expressing human interferon alpha2b driven by the cytomegalovirus promoter, IACB, was shown to produce and secrete biologically active protein in vitro and in vivo. Intravenous administration of IACB in Buffalo rats resulted in circulating levels of biologically active human interferon at 70,000 international units/mL for up to 15 days. Distribution of interferon protein after IACB administration was different from that seen with the subcutaneous delivery of interferon protein. Higher levels of interferon protein were observed in liver and spleen after IACB delivery compared to protein delivery. The antitumor efficacy of IACB, as measured by suppression of tumor growth, was tested in athymic nude mice bearing established human tumor xenografts from different types of human cancer. Subcutaneous tumors most responsive to the intratumoral administration of IACB ranked as U87MG (glioblastoma) and K562 (chronic myelogenous leukemia), followed by Hep 3B (hepatocellular carcinoma) and LN229 cells (glioblastoma). Intravenous administration of IACB in animals bearing U87MG or Hep 3B xenografts was also effective in suppressing tumor growth, although to a lesser extent than the intratumoral administration. IACB was also tested in a metastatic model in beige/SCID mice generated with H69 (small cell lung carcinoma) cells and was found to prolong survival in tumor-bearing animals. This suggested that interferon gene delivery can be effective in suppressing tumor growth in a wide variety of cells.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results